Resources with keywords: covid-19
Following a thorough safety review, the FDA and CDC have determined that the recommended pause regarding the use of the Johnson & Johnson COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.
More in depth information for laboratories testing for Covid-19 variants.
Out of an “abundance of caution,” the F.D.A. is advising doctors to pause the Johnson & Johnson vaccine
This page provides information and resources to help public health departments and laboratories investigate and report COVID-19 vaccine breakthrough cases.
Breakthrough cases represent 0.008% of the fully vaccinated population and are in line with expectations because the approved vaccines in the U.S. are not 100% effective.
COVID-19 infection leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.
Due to variants of the coronavirus, people likely will need a booster shot within a year to suppress the pool of those individuals susceptible to Covid-19 per Pfizer Chief Executive Albert Bourla.
CDC and the FDA are reviewing data involving six U.S. cases of a rare type of blood clot in individuals after receiving the J&J COVID-19 vaccine that were reported to the Vaccine Adverse Event Reporting System.
